2025/02/28 更新

写真a

ウメダ トモヒロ
梅田 知宙
UMEDA TOMOHIRO
担当
大学院医学研究科 基礎医科学専攻 講師
医学部 医学科
職名
講師
所属
医学研究院

担当・職階

  • 大学院医学研究科 基礎医科学専攻 

    講師  2024年04月 - 継続中

  • 医学部 医学科 

    講師  2024年04月 - 継続中

取得学位

  • 博士(医学) ( 大阪市立大学 )

論文

  • Simply crushed Zizyphi spinosi semen prevents neurodegenerative diseases and reverses age-related cognitive decline in mice 査読

    Tomohiro Umeda, Ayumi Sakai, Rumi Uekado, Keiko Shigemori, Ryota Nakajima, Kei Yamana, Takami Tomiyama

    eLife   2024年09月

     詳細を見る

    担当区分:筆頭著者   国際・国内誌:国際誌  

    Neurodegenerative diseases are age-related disorders characterized by the cerebral accumulation of amyloidogenic proteins, and cellular senescence underlies their pathogenesis. Thus, it is necessary for preventing these diseases to remove toxic proteins, repair damaged neurons, and suppress cellular senescence. As a source for such prophylactic agents, we selected Zizyphi spinosi semen (ZSS), a medicinal herb used in traditional Chinese medicine. ZSS hot water extract ameliorated Aβ and tau pathology and cognitive impairment in mouse models of Alzheimer’s disease and frontotemporal dementia. Non-extracted ZSS simple crush powder showed stronger effects than the extract and improved α-synuclein pathology and cognitive/motor function in Parkinson’s disease model mice. Furthermore, when administered to normal aged mice, the ZSS powder suppressed cellular senescence, reduced DNA oxidation, promoted brain-derived neurotrophic factor expression and neurogenesis, and enhanced cognition to levels similar to those in young mice. The quantity of known active ingredients of ZSS, jujuboside A, jujuboside B, and spinosin, was not proportional to the nootropic activity of ZSS. These results suggest that ZSS simple crush powder is a promising dietary material for the prevention of neurodegenerative diseases and brain aging.Impact statementNon-extracted simple crush powder of Zizyphi spinosi semen has not only disease-preventing effects but also brain-rejuvenating effects in mice.

    DOI: https://doi.org/10.7554/eLife.100737.1

  • New Value of Acorus tatarinowii/gramineus Leaves as a Dietary Source for Dementia Prevention. 査読

    Tomohiro Umeda, Ayumi Sakai, Keiko Shigemori, Kunio Nakata, Ryota Nakajima, Kei Yamana, Takami Tomiyama

    Nutrients   16 ( 11 )   2024年05月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    The rhizomes of Acorus tatarinowii Schott and Acorus gramineus Solander are widely used for treating amnesia in traditional Chinese medicine. In contrast, their leaves are usually discarded without their medicinal properties being known. Here, we found that the hot water extract of leaves improved cognition and tau pathology in model mice of frontotemporal dementia, similar to or even better than that of rhizomes. To explore the optimal method of processing, we made three preparations from dried leaves: hot water extract, extraction residue, and non-extracted simple crush powder. Among them, the simple crush powder had the strongest effect on tauopathy in mice. The crush powder also ameliorated Aβ and α-synuclein pathologies and restored cognition in mouse models of Alzheimer's disease and dementia with Lewy bodies. These findings suggest the potential of Acorus tatarinowii/gramineus leaves as a dietary source for dementia prevention and reveal that simple crushing is a better way to maximize their efficacy.

    DOI: 10.3390/nu16111589

    PubMed

  • The microtubule-dynamin binding inhibitor peptide PHDP5 rescues spatial learning and memory deficits in Alzheimer’s disease model mice 査読

    Chia-Jung Chang, Zacharie Taoufiq, Hiroshi Yamada, Takei Kohji, Takami Tomiyama, Tomohiro Umeda, Tetsuya Hori, Tomoyuki Takahashi

    Brain Research   1838   148987 - 148987   2024年05月( ISSN:0006-8993

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1016/j.brainres.2024.148987

    PubMed

  • Hawaiian native herb Mamaki prevents dementia by ameliorating neuropathology and repairing neurons in four different mouse models of neurodegenerative diseases 査読

    Tomohiro Umeda, Keiko Shigemori, Rumi Uekado, Kazunori Matsuda, Takami Tomiyama

    GeroScience   46 ( 2 )   1971 - 1987   2024年04月( ISSN:25092715

     詳細を見る

    担当区分:筆頭著者   国際・国内誌:国際誌  

    DOI: 10.1007/s11357-023-00950-y

    PubMed

  • Investigating the efficacy of nasal administration for delivering magnetic nanoparticles into the brain for magnetic particle imaging. 査読

    Satoshi Seino, Hiroto Ikehata, Mizuki Tanabe, Tomohiro Umeda, Takami Tomiyama, Akiko Tanaka, Tomoyuki Furubayashi, Toshiyasu Sakane, Toshihiko Kiwa, Masaomi Washino, Kota Nomura, Shun Tonooka, Akihiro Izawa, Yuki Okumura, Takashi Nakagawa

    Journal of controlled release : official journal of the Controlled Release Society   367   515 - 521   2024年03月( ISSN:01683659

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    This study explored the effectiveness of nasal administration in delivering magnetic nanoparticles into the brain for magnetic particle imaging of target regions. Successful delivery of iron oxide nanoparticles, which serve as contrast agents, to specific sites within the brain is crucial for achieving magnetic particle imaging. Nasal administration has gained attention as a method to bypass the blood-brain barrier and directly deliver therapeutics to the brain. In this study, we investigated surface modification techniques for administering magnetic nanoparticles into the nasal cavity, and provided experimental validation through in vivo studies. By compositing magnetic nanoparticles with gold nanoparticles, we enabled additional surface modification via AuS bonds without compromising their magnetic properties. The migration of the designed PEGylated magnetic nanoparticles into the brain following nasal administration was confirmed by magnetization measurements. Furthermore, we demonstrated the accumulation of these nanoparticles at specific target sites using probe molecules immobilized on the PEG terminus. Thus, the efficacy of delivering magnetic nanoparticles to the brain via nasal administration was demonstrated in this study. The findings of this research are expected to contribute significantly to the realization of magnetic particle imaging of target regions within the brain.

    DOI: 10.1016/j.jconrel.2024.01.027

    PubMed

講演・口頭発表等

産業財産権等

  • 神経変性疾患の予防又は治療薬

    富山貴美、梅田知宙、熊谷徹

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:PCT/JP2023/017175 

  • 生薬を用いた脳機能の維持又は改善のための剤及び方法

    富山貴美、梅田知宙、松田和則

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:特願2023-048891 

  • 神経変性疾患の治療剤

    江口広志、富山貴美、梅田知宙

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:PCT/JP2023/00714 

  • 生薬を用いた脳機能の維持又は改善のための剤及び方法

    富山貴美、梅田知宙、山名慶、中島良太

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:特願2022-210257 

  • 画像診断用磁気ナノ粒子及び画像診断用造影剤

    清野智史、池畠博人、富山貴美、梅田知宙、井澤彰宏

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:PCT/JP2022/020104 

  • 生体情報検出装置および生体情報検出方法

    殿岡俊、野村航大、山内一輝、松田哲也、富山貴美、梅田知宙、清野智史、坂根稔康、勝見晶子、紀和利彦、井澤彰宏

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:PCT/JP2021/018763 

  • 神経変性疾患の予防又は治療薬

    富山貴美、梅田知宙、熊谷徹

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:PCT/JP2020/000392 

    特許番号/登録番号:特許番号:日本JP 7146281 B2、米国US11,583,494、インドIN 410910 

  • 経鼻投与用医薬組成物

    富山貴美、梅田知宙

     詳細を見る

    産業財産権の種類:特許権 

    出願番号:PCT/JP2018/025512 

▼全件表示

科研費獲得実績

  • C9orf72関連ALS/FTDにおける異常RNA転写・異常翻訳を引き起こすミトコンドリアの役割

    基盤研究(C)  2026年

  • C9orf72関連ALS/FTDにおける異常RNA転写・異常翻訳を引き起こすミトコンドリアの役割

    基盤研究(C)  2025年

  • C9orf72関連ALS/FTDにおける異常RNA転写・異常翻訳を引き起こすミトコンドリアの役割

    基盤研究(C)  2024年

その他補助金等

  • 老化ミクログリア標的抗体による認知症治療効果の前臨床研究

    令和6年度大阪認知症研究会 医学研究助成  2024月

  • C9orf72にリンクした前頭側頭型認知症に対するリファンピシン-レスベラトロール合剤点鼻薬の効果と作用機序の解明

    令和4年度大阪認知症研究会 医学研究助成  2022月